ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biohaven pays $105 million for GW Pharma’s priority review voucher

by Lisa M. Jarvis
March 22, 2019 | APPEARED IN VOLUME 97, ISSUE 12

 

GW Pharmaceuticals has sold the rare-disease priority review voucher (PRV) it obtained with US Food and Drug Administration approval of its epilepsy treatment Epidiolex. PRVs, introduced by the FDA to spur research into rare and tropical diseases, are granted when a drug for an underserved disease is approved. They can be used to speed the agency’s review of another new drug application. GW got $105 million for its voucher from Biohaven Pharmaceuticals, which will use it to expedite the review of a migraine therapy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment